Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Trazenta
DRUG
2 trials
Sponsors
Boehringer Ingelheim
Conditions
Diabetes Mellitus, Type 2
Unknown Phase
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Completed
NCT01650259
Boehringer Ingelheim
Diabetes Mellitus, Type 2
Start: 2012-07-23
End: 2017-09-14
Updated: 2019-09-18
PMS of Trazenta on the Long-term Use as Add-on Therapy
Completed
NCT01904383
Boehringer Ingelheim
Diabetes Mellitus, Type 2
Start: 2013-07-01
End: 2018-10-04
Updated: 2019-10-02
Related Papers
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
Expert Opinion on Drug Safety
2022-04-14
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Expert Opinion on Drug Safety
2020-12-03
5 citations
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
2020-01-13
2 citations
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
Diabetes Therapy
2019-11-11
10 citations